Julie Anne Smith's most recent trade in Stoke Therapeutics Inc was a trade of 29,747 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 20,590 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 27 Feb 2025 | 54,514 | 10,778 (0%) | 0% | 38.1 | 2,078,619 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 27 Feb 2025 | 31,167 | 41,945 (0%) | 0% | 20.5 | 638,924 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 31,167 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 23,347 | 19,294 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 23,347 | 65,292 (0%) | 0% | 19.8 | 461,570 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 37.62 per share. | 27 Feb 2025 | 19,294 | 10,778 (0%) | 0% | 37.6 | 725,840 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 19,294 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 19,294 | 30,072 (0%) | 0% | 19.8 | 381,442 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Other type of transaction at price $ 0.00 per share. | 13 Aug 2024 | 4,682 | 10,778 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 20,030 | 20,030 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 10,015 | 15,460 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 21 May 2024 | 27,280 | 5,445 (0%) | 0% | 21.1 | 576,154 | Common Stock |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) |